SMO and meningioma: Targeted gene analysis identified non-synonymous mutations in NF2 (the most common alteration), KDM5C, SMO, AKT1, RGPD3, and CD300C. The specific SMO mutations were previously known oncogenic mutations in basal cell carcinoma and desmoplastic medulloblastoma and were only found in meningiomas without NF2 alterations.